Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value?
Tremolizzo
L
L
Rodriguez-Menendez
V
V
DiFrancesco
J C
JC
Sala
G
G
Galbussera
A
A
Appollonio
I
I
Ferrarese
C
C
D000927:Anticonvulsants / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D006655:Histone Deacetylases / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D006816:Huntington Disease / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology*; D009043:Motor Activity / Q000187:drug effects; D013469:Sulpiride / Q000627:therapeutic use*; D014635:Valproic Acid / Q000627:therapeutic use*
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D014635:Valproic Acid; D013469:Sulpiride; D006655:Histone Deacetylases